Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative ophthalmic pharmaceuticals to treat orphan retinal diseases with a high unmet need. Their mission is to help patients restore vision and improve their ocular health. Publicly traded on the NASDAQ under the symbol KPRX, they are headquartered in Encinitas, California.

Their pipeline includes multiple New Chemical Entities, including KIO-301, a revolutionary small molecule that has the potential to restore vision in patients with inherited or age-related retinal degeneration, and KIO-104, a small molecule DHODH inhibitor that treats immunologic eye diseases. Kiora is dedicated to bringing these therapies to patients suffering from rare retinal diseases.

Kiora Pharmaceuticals is a clinical-stage biotechnology company dedicated to developing and commercializing innovative treatments for orphan retinal diseases, with a particular focus on restoring vision in patients suffering from severe vision loss. Their mission is to improve ocular health and restore vision for those affected by these rare and debilitating conditions.

Kiora Pharmaceuticals promotes a culture of innovation and collaboration focused on developing treatments for orphan retinal diseases. The company emphasizes its mission to improve patient vision and ocular health, showcasing a commitment to both scientific advancement and a positive impact on patients' lives. This focus is reflected in the company's name, derived from the Māori phrase for "have life" or "be healthy," highlighting a values-driven approach to creating impactful solutions.

Kiora Pharmaceuticals has a commitment to diversity, equity, and inclusion, demonstrated by their Board Diversity Matrix, which shows one female director out of seven total and one Asian director. This indicates a focus on gender diversity and representation of Asian backgrounds. While this data suggests an initial step towards inclusivity, a more comprehensive and robust approach to diversity and inclusion requires further exploration.